Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Melanoma 40Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 29Urinary Bladder Neoplasms 15Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Colorectal Neoplasms 15Stomach Neoplasms 13Pancreatic Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Ovarian Neoplasms 11Sarcoma 10Hodgkin Disease 10Glioblastoma 10Carcinoma, Transitional Cell 10Rectal Neoplasms 9Triple Negative Breast Neoplasms 8Prostatic Neoplasms 8Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Kidney Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Breast Neoplasms 7Head and Neck Neoplasms 6Skin Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5

Interventions

lutetium Lu 177 dotatate 2pasireotide 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1abemaciclib 1Temozolomide 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Oxaliplatin 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Leucovorin 1Ipilimumab 1Folfox protocol 1Fluorouracil 1Everolimus 1E-7386 1Capecitabine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastro-enteropancreatic neuroendocrine tumor × Nivolumab × Clear all
NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡